Biosolution Co.Ltd (086820) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biosolution Co.Ltd (086820) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩17.41 Million ≈ $11.80K USD) by net assets (₩26.31 Billion ≈ $17.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biosolution Co.Ltd balance sheet independence to measure how much of total assets are equity-financed.
Biosolution Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Biosolution Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 086820 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Biosolution Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosolution Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yoosung T&S Co. Ltd
KQ:024800
|
0.004x |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
-0.006x |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
0.165x |
|
Hwashin Precision Engineering Co. Ltd
KQ:126640
|
-0.060x |
|
CI Holdings Bhd
KLSE:2828
|
0.112x |
|
Midnight Sun Mining Corp
V:MMA
|
-0.178x |
|
HLS Therapeutics Inc
TO:HLS
|
0.105x |
|
Big River Industries Ltd
AU:BRI
|
0.084x |
Annual Cash Flow Conversion Efficiency for Biosolution Co.Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Biosolution Co.Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 086820 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩31.26 Billion ≈ $21.18 Million |
₩-2.29 Billion ≈ $-1.55 Million |
-0.073x | -242.66% |
| 2023-12-31 | ₩42.13 Billion ≈ $28.55 Million |
₩2.16 Billion ≈ $1.46 Million |
0.051x | +158.85% |
| 2022-12-31 | ₩43.78 Billion ≈ $29.67 Million |
₩-3.81 Billion ≈ $-2.58 Million |
-0.087x | -4808.31% |
| 2021-12-31 | ₩45.01 Billion ≈ $30.50 Million |
₩83.29 Million ≈ $56.44K |
0.002x | +105.12% |
| 2020-12-31 | ₩46.66 Billion ≈ $31.62 Million |
₩-1.69 Billion ≈ $-1.14 Million |
-0.036x | +33.31% |
| 2019-12-31 | ₩48.10 Billion ≈ $32.59 Million |
₩-2.61 Billion ≈ $-1.77 Million |
-0.054x | -359.07% |
| 2018-12-31 | ₩49.06 Billion ≈ $33.25 Million |
₩1.03 Billion ≈ $695.43K |
0.021x | +217.65% |
| 2017-12-31 | ₩4.42 Billion ≈ $2.99 Million |
₩-78.53 Million ≈ $-53.22K |
-0.018x | +94.74% |
| 2016-12-31 | ₩6.12 Billion ≈ $4.15 Million |
₩-2.07 Billion ≈ $-1.40 Million |
-0.338x | -24.26% |
| 2015-12-31 | ₩7.40 Billion ≈ $5.02 Million |
₩-2.02 Billion ≈ $-1.37 Million |
-0.272x | -- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more